RADNOR, Pa., April 12, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) ("Sarepta").On March 18, 2025, Sarepta issued a press release revealing that a 16-year-old boy had passed away from acute liver failure following treatment with Sarepta's gene therapy, ELEVIDYS.On this news, Sarepta's stock price fell $27.81 per share, or ...